To date, multiple COVID-19 vaccines have been granted emergency use authorization, including inactivated vaccines, adenovirus-vectored vaccines, and nucleic acid vaccines. These vaccines have different technical principles, which will necessarily lead to differences in safety and efficacy.
Vaccine Name | Technology | Developer/Company | Expiration Date | Immunization Protocol | Approved | ||
---|---|---|---|---|---|---|---|
CoronaVac | Inactivated vaccine | Sinovac Biotech Ltd. (Beijing, China) |
2–8 °C for 24 months | 2 doses (600SU/0.5 mL/dose), 2–4 weeks apart | WHO 2021.6.1 |
||
BBIBP-CorV | Inactivated vaccine | Sinopharm Beijing Institute of Biotechnology (Beijing, China) | 2–8 °C for 24 months | 2 doses (6.5U/0.5 mL/dose), 3–4 weeks apart | WHO 2021.5.7 |
||
Convidecia | Adenovirus vector vaccine | Cansino Biologics (Tianjin, China) | 2–8 °C for 12 months | 1 dose (5 × 10 | 10 | virus particles/0.5 mL) | China 2021.2. 25 |
AZD1222 | Adenovirus vector vaccine | AstraZeneca (Cambridge, UK), Oxford University (Oxford, UK) | 2–8 °C for 6 months | 2 dose (5 × 10 | 10 | virus particles/0.5 mL), 4–12 weeks apart | WHO 2021.3.1 |
Ad26.COV2.S | Adenovirus vector vaccine | Johnson & Johnson (New Brunswick, NJ, USA) | 2–8 °C for 3 months | 1 dose (5 × 10 | 10 | virus particles/0.5 mL) | WHO 2021.3.17 |
Sputnik V | Adenovirus vector vaccine | Gamaleya Research Institute (Moscow, Russia) | −18 °C/2–8 °C | 2 dose (10 | 11 | viral particles /0.5 mL/dose), 2–3 weeks apart |
Multiple countries without WHO |
BNT162b2 | mRNA vaccine | Pfizer (New York, NY, USA)/BioNTech (Mainz, Germany) | Ultralow-temperature freezer for 6 months/−70 ± 10 °C for 10 days/2–8 °C for 5 days | 2 doses (30 μg/0.3 mL/dose), 3 weeks apart | WHO 2021.1.14 |
||
mRNA-1273 | mRNA vaccine | Moderna (Cambridge, MA, USA) | Between −25 °C and −15 °C for supply/2–8 °C for 30 days | 2 doses (100 μg/0.5 mL/dose), 28 days apart | WHO 2021.2.3 |
||
NVX-CoV2373 | Recombinant vaccine | Novavax and the Serum Institute of India (Pune, India) | 2–8 °C for 9 months | 2 doses (55 μg/0.5 mL/dose), 3–4 weeks apart | WHO 2021.12.20 |